Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects-Reference-Cited by-同舟云学术

Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects

Published:2021-09-20 Issue:12 Volume:48 Page:1589-1602
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharmacol Physiol

Author:

Elhini Sahar Hossam¹,Hussien Amal K.²,Omran Ahmed Abd Elsamie³,Elsayed Asmaa A.⁴,saeed Haitham⁵^ORCID

Affiliation:

1. Diabetes and Endocrinology, Faculty of Medicine Minia University Minia Egypt

2. Department of Pharmaceutics, Faculty of Pharmacy Minia University Minia Egypt

3. Department of Clinical Pathology, Faculty of Medicine Minia University Minia Egypt

4. Department of Clinical Pharmacy, Faculty of Pharmacy Minia University Minia Egypt

5. Department of Clinical Pharmacy, Faculty of Pharmacy Beni‐Suef University Beni‐Suef Egypt

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1440-1681.13561

Reference40 articles.

1. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2020

2. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery

3. Update on the treatment of type 2 diabetes mellitus

4. Long‐term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET‐K1) to a target of HbA1c <7%;Maeda H;J Endocrinol Invest,2013

5. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)